Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HANSHIN Oncology Group 0312: Zoledronic acid every 4 vs 8 weeks in lung cancer with bone metastasis
jRCTs061180054Phase 2Completed
- Sponsor
- Kobe City Medical Center General Hospital
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of zoledronic acid in bronchial carcinoma and bone metastases (2 arms), sponsored by Kobe City Medical Center General Hospital. Primary endpoint: Time to first skeletal-related event (SRE). Started Dec 2012; status: completed.
02
Drugs
zoledronic acid
03
Conditions
bronchial carcinomabone metastases
Beyond the preview
Go deeper on jRCTs061180054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180054.